onc Videos

Videos

Conference Coverage

Trastuzumab, Pertuzumab, and Docetaxel Remains Standard of Care for Older Patients With HER2-Positive Metastatic Breast Cancer

01/03/2024

Akihiko Shimomura , MD;

Akihiko Shimomura, MD, discussed results from a phase 3 study which compared trastuzumab emtansine against standard-of-care trastuzumab, pertuzumab, and docetaxel to determine optimal treatment for older patients with HER2-positive metastatic...

Akihiko Shimomura, MD, discussed...

01/03/2024

Oncology

Conference Coverage

Examining Predictors of Emergent Thrombocytopenia After Ruxolitinib Treatment Among Patients With Myelofibrosis

01/03/2024

Douglas Tremblay , MD;

At the 2023 ASH Annual Meeting, Douglas Tremblay, MD, discussed the prevalence and predictors of emergent thrombocytopenia following ruxolitinib treatment among patients with myelofibrosis.

At the 2023 ASH Annual Meeting,...

01/03/2024

Oncology

Conference Coverage

Use of a 12-Gene DCIS Score to Guide Radiotherapy Decisions for Patients With Ductal Carcinoma in Situ

01/03/2024

Seema Khan , MD;

Seema Khan, MD, discussed 5-year clinical outcomes from E4112 which identified that >90% of patients who underwent a 12-gene DCIS score to predict radiotherapy benefit followed DS-based recommendations.

Seema Khan, MD, discussed 5-year...

01/03/2024

Oncology

Conference Coverage

Individualization of Therapies for Patients With HR-Positive, HER2-Negative Breast Cancer

01/03/2024

Rick Baehner , MD;

Rick Baehner, MD, discussed results from the phase 3 ADAPTcycle trial.

Rick Baehner, MD, discussed...

01/03/2024

Oncology

Conference Coverage

Hypomethylating Agent Monotherapy Compared With Hypomethylating Agent Plus Venetoclax Regimen Among Patients With Untreated TP53-Mutated AML

01/03/2024

Talha Badar , MD;

At the 65th ASH Annual Meeting, Talha Badar, MD, discusses a retrospective study on the efficacy of venetoclax combined with hypomethylating agent (HMA) therapy vs HMA monotherapy for patients with TP53-mutated acute myeloid leukemia.

At the 65th ASH Annual Meeting,...

01/03/2024

Oncology

Conference Coverage

Maternal and Neonatal Safety of Taxane Chemotherapy During Pregnancy for the Treatment of Breast Cancer

12/28/2023

Ana Ferrigno , MD;

Ana Ferrigno, MD, discussed results from an international cohort study which demonstrated that the use of taxane-containing chemotherapy during pregnancy does not increase the risk of obstetric and neonatal complications.

Ana Ferrigno, MD, discussed...

12/28/2023

Oncology

Conference Coverage

Loco-Regional Irradiation for Patients With Biopsy-Proven Axillary Node Involvement Who Become Node-Negative After Neoadjuvant Chemotherapy

12/28/2023

Eleftherios Mamounas , MD;

Eleftherios Mamounas, MD, discussed primary results from the NRG Oncology/NSABP B-51/RTOG 1304 study.

Eleftherios Mamounas, MD,...

12/28/2023

Oncology

Conference Coverage

Use of a Structured, Individualized Exercise Program for Patients With Metastatic Breast Cancer

12/28/2023

Anouk Hiensch , PhD;

Anouk Hiensch, PhD, discussed results from the PREFERABLE-EFFECT study, which demonstrated that starting a structured, individualized exercise intervention during palliative treatment for metastatic breast cancer decreased fatigue and...

Anouk Hiensch, PhD, discussed...

12/28/2023

Oncology

Shernan G Holtan, MD, University of Minnesota

Conference Coverage

Selective Oral AURKA Inhibitor for Graft-Versus-Host Disease and Relapse Prophylaxis Following Allogeneic HCT

12/21/2023

Shernan Holtan , MD;

At the 2023 ASH Annual Meeting, Shernan G Holtan, MD, shares data from a trial of post-transplant cyclophosphamide plus sirolimus combined with VIC-1911, a selective oral AURKA inhibitor, for patients with GVHD and relapse prophylaxis after...

At the 2023 ASH Annual Meeting,...

12/21/2023

Oncology

Ryan Lynch, MD, Fred Hutch Cancer Center

Videos

Evaluating Early Complete Responses of Mosunetuzumab Monotherapy for Patients With Previously Untreated Follicular Lymphoma and MZL

12/21/2023

Ryan Lynch , MD;

At the 65th ASH Annual Meeting, Ryan C Lynch, MD, presented data on the high complete response rates of mosunetuzumab in previously untreated patients with follicular lymphoma and marginal zone lymphoma and only low-grade cytokine release...

At the 65th ASH Annual Meeting,...

12/21/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology